GleamWall
中文EN

ERAS Erasca, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1761918 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-141.2%
TTM EPS YoY-125.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-48.7%
ROA-43.4%
ROIC (approx.)-48.1%
Asset turnover—

Leverage & solvency

Liabilities / assets8.2%
Debt / equity0.00x
Current ratio14.89x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.35x
Accruals ratio-28.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$92.85M$115.36M
SG&A expense$38.55M$41.73M
Operating income-$140.91M-$179.59M
Pretax income-$124.55M-$161.65M
Income tax$0$0
Net income-$124.55M-$161.65M
EBITDA-$137.80M-$175.78M
EPS (basic)-0.44-0.69
EPS (diluted)-0.44-0.69
Dividends declared per share0.000.00
Weighted avg. shares (diluted)283.53M233.82M
Balance sheet
Cash & equivalents$73.81M$67.74M
Short-term investments$202.27M$230.57M
Current assets$286.24M$308.79M
PP&E, net$13.30M$16.32M
Total assets$396.15M$502.53M
Current liabilities$28.51M$31.39M
Total liabilities$70.98M$79.03M
Shareholders' equity$325.17M$423.50M
Shares outstanding284.16M283.22M
Cash flow statement
Operating cash flow-$95.45M-$109.42M
Capital expenditure$128,000$60,000
Free cash flow-$95.58M-$109.48M
Investing cash flow$100.42M-$156.62M
Financing cash flow$1.10M$240.70M
Depreciation & amortization$3.11M$3.81M
Stock-based compensation$24.90M$26.97M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.